Role of dehydroepiandrosterone in management of glucocorticoid-induced secondary osteoporosis in female rats

Experimental and Toxicologic Pathology

Volumn 64, Issue 6, 2012, Pages 659-664

  Ahmed, Hanaa H ^a   Morcos, Nadia Y S ^b   Eskander, Emad F ^a   Seoudi, Dina M S ^b   Shalby, Aziza B ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b Ain Shams University   (Egypt)

Author keywords

Bone biomarkers; DHEA; Osteoporosis; Prednisolone; Rats

Indexed keywords

CALCITRIOL; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PRASTERONE; PREDNISOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; COMPRESSION; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG POTENCY; EPIPHYSIS; FEMALE; FEMUR; HISTOPATHOLOGY; HORMONE SUBSTITUTION; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RAT; TREATMENT DURATION; VITAMIN BLOOD LEVEL;

ANIMALS; BONE AND BONES; DEHYDROEPIANDROSTERONE; FEMALE; GLUCOCORTICOIDS; OSTEOPOROSIS; PREDNISOLONE; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84864499222     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2011.01.004     Document Type: Article

References (39)

1. Bonadonna S., Burattin A., Nuzzo M., Bugari G., Rosei E.A., Valle D., et al. Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 2005, 152:199-205.
2. Bouillon R., Coopmans W., De Groote D.E.H., Radoux D., Eliard P.H. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region specific antibodies. Clin Chem 1990, 36:271-276.
3. Cormier C., Souberbielle J.C., Kahan A. DHEA in bone and joint diseases. Joint Bone Spine 2001, 68:588-594.
4. Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 2009, 5:20-27.
5. Delany A.M., Durant D., Canalis E. Glucocorticoid suppression of IGFI transcription in osteoblasts. Mol Endocrinol 2001, 15:1781-1789.
6. Faienza M.F., Brunetti G., Colucci S., Piacente L., Ciccarelli M., Giordani L., et al. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance. J Clin Endocrinol Metab 2009, 94:2269-2276.
7. Ferrari P. Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease. Best Pract Res Clin Endocrinol Metab 2003, 17:575-589.
8. Gordon C.M., Grace E., Emans S.J., Feldman H.A., Goodman E., Becker K.A., et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab 2002, 87:4935-4941.
9. Gyetko M.R., Hsu C.H., Wilkinson C.C., Patel S., Young E. Monocyte 1 alpha-hydroxylase regulation: induction by inflammatory cytokines and suppression by dexamethasone and uremia toxin. J Leukoc Biol 1993, 54:17-22.
10. Harding G., Mak Y.T., Evans B., Cheung J., MacDonald D., Hampson G. The effects of dexamethasone and dehydroepiandrosterone (DHEA) on cytokines and receptor expression in a human osteoblastic cell line: potential steroid-sparing role for DHEA. Cytokine 2006, 36:57-68.
11. Hattersley A.T., Meeran K., Burrin J., Hill P., Shiner R., Ibbertson H.K. The effect of long- and short-term corticosteroids on plasma calcitonin and parathyroid hormone levels. Calcif Tissue Int 1994, 54:198-202.
12. Hazavehei S.M., Taghdisi M.H., Saidi M. Application of the health belief model for osteoporosis prevention among middle school girl students, Garmsar, Iran. Educ Health (Abingdon) 2007, 20:23.
13. Higdon K., Scott A., Tucci M., Benghuzzi H., Tsao A., Puckett A., et al. The use of estrogen, DHEA, and diosgenin in a sustained delivery setting as a novel treatment approach for osteoporosis in the ovariectomized adult rat model. Biomed Sci Instrum 2001, 37:281-286.
14. Iqbal S.J. Vitamin D metabolism and the clinical aspects of measuring metabolites. Ann Clin Biochem 1994, 31:109-124.
15. King C.S., Weir E.C., Gundberg C.W., Fox J., Insogna K.L. Effects of continuous glucocorticoid infusion on bone metabolism in the rat. Calcif Tissue Int 1996, 59:184-191.
16. Lane N.E., Yao W. Glucocorticoid-induced bone fragility. Ann N Y Acad Sci 2010, 1192:81-83.
17. Lardy H., Henwood S.M., Weeks C.E. An acute oral gavage study of β-acetoxyandrost-5-ene-7,17-dione(7-oxo-DHEA-acetate) in rats. Biochem Biophys Res Commun 1999, 254:120-123.
18. Migliaccio S., Brama M., Fornari R., Greco E.A., Spera G., Malavolta N. Glucocorticoid-induced osteoporosis: an osteoblastic disease. Aging Clin Exp Res 2007, 19:5-10.
19. O'Brien E.A., Williams J.H.H., Marshall M.J. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. Bone 2001, 28:208-214.
20. O'Brien C.A., Jia D., Plotkin L.I., Bellido T., Powers C.C., Stewart S.A., et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004, 145:1835-1841.
21. Ozmen B., Kirmaz C., Aydin K., Kafesciler S.O., Guclu F., Hekimsoy Z. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw 2007, 18:148-153.
22. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
23. Power M.J., Fottrell P.F. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 1991, 28:287-335.
24. Sadat-Ali M., Alelq A.H., Alshafei B.A., Al-Turki H.A., Abujubara M.A. Osteoporosis prophylaxis in patients receiving chronic glucocorticoid therapy. Ann Saudi Med 2009, 29:215-218.
25. Saunders D.B., Trapp G.R. Basic and clinical biostatistics 2001, Appleton and Lang, Connecticut. 3rd ed.
26. Schermer S. The blood morphology of laboratory animals 1967, F.A. Davi, Philadelphia, p. 42. 3rd ed.
27. Stepan J.J., Alenfeld F., Boivin G., Feyen J.H., Lakatos P. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 2003, 37:225-238.
28. Surve V.V., Andersson N., Lehto-Axtelius D., Håkanson R. Comparison of osteopenia after gastrectomy, ovariectomy and prednisolone treatment in the young female rat. Acta Orthop Scand 2001, 72:525-532.
29. Taelman P., Kaufman J.M., Janssens X., Vermeulen A. Persistence of increased bone resorption and possible role of dehydroepiandrosterone as a bone metabolism determinant in osteoporotic women in late post-menopause. Maturitas 1989, 11:65-73.
30. 3 in human osteoblasts. Mech Ageing Dev 2002, 123:1107-1114.
31. Takayanagi R. Hormones and osteoporosis update. Adrenal androgen and bone. Clin Calcium 2009, 19:963-969.
32. Tamura Y., Okinaga H., Takami H. Glucocorticoid-induced osteoporosis. Biomed Pharmcoth 2004, 58:500-504.
33. Teng Y.T., Nguyen H., Gao X., Kong Y.Y., Gorczynski R.M., Singh B., et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000, 106:749-752.
34. Tolar J., Teitelbaum S.L., Orchard P.J. Mechanisms of disease: osteopetrosis. N Engl J Med 2004, 351:2839-2849.
35. Ureña P., Iida-Klein A., Kong X.F., Jüppner H., Kronenberg H.M., Abou-Samra A.B., et al. Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17/2.8 and OK cells. Endocrinology 1994, 134:451-456.
36. Vincent A., Riggs B.L., Atkinson E.J., Oberg A.L., Khosla S. Effect of estrogen replacement therapy on parathyroid hormone secretion in elderly postmenopausal women. Menopause 2003, 10:165-171.
37. Wang F.S., Ko J.Y., Yen D.W., Ke H.C., Wu H.L. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation and bone mass loss. Endocrinology 2008, 149:1793-1801.
38. Wimalawansa S.J., Simmons D.J. Prevention of corticosteroid-induced bone loss with alendronate. Proc Soc Exp Biol Med 1998, 217:162-167.
39. 3 and androgens. J Steroid Biochem Mol Biol 2003, 86:393-397.